La Jolla Pharmaceutical Company

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.

Website	https://www.lajollapharmaceutical.com/
Employees	51-200 employees View all La Jolla Pharmaceutical Company employees
Industry	Biotechnology
Location	201 Jones Rd, Suite 400, Waltham, MA 02451, US
Founded	1989
Keywords	Chronic Kidney Disease, Galectin-3, Hepatorenal Syndrome

Get verified email of La Jolla Pharmaceutical Company employees

La Jolla Pharmaceutical Company Alternatives

CEB

Biotechnology

Fluidic Analytics

biotechnology

Pulmonary Critical Care

biotechnology

Ciphergen Biosystems

biotechnology

Premier Research

biotechnology

Genizon BioSciences

Biotechnology

VBI Vaccines Inc.

biotechnology

Triosyn Corp.

biotechnology

Frequently Asked Questions about La Jolla Pharmaceutical Company

Who are the decision makers in La Jolla Pharmaceutical Company?

The decision makers in La Jolla Pharmaceutical Company are Bevin Endicott, David Blais, Jim Kee, etc. Click to Find La Jolla Pharmaceutical Company decision makers emails.